
- Species ReactivityHuman
- SpecificityDetects human CCL20/MIP-3 alphain ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) CCL19, rhCXCL1, rhCCL16, rhCCL11, recombinant mouse CCL20/MIP-3 alpha, or recombinant rat CCL20/MIP-3 alphais observed.
- SourceMonoclonal Mouse IgG1 Clone # 67310
- PurificationProtein A or G purified from ascites
- ImmunogenE. coli-derived recombinant human CCL20/MIP-3 alpha
Ala27-Met96 (Asn95Asp)
Accession # P78556.1 - FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
- Endotoxin Level<0.10 eu="" per="" 1="" μg="" of="" the="" antibody="" by="" the="" lal="">0.10>
- LabelUnconjugated
- Western Blot1 µg/mLSee below
- CyTOF-readyReady to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
- Intracellular Staining by Flow Cytometry2.5 µg/106 cellsHuman peripheral blood mononuclear cells treated with LPS, fixed with paraformaldehyde, and permeabilized with saponin
- Human CCL20/MIP-3 alphaSandwich ImmunoassayReagent
- ELISA Capture (Matched Antibody Pair)2-8 µg/mLHuman CCL20/MIP‑3 alphaAntibody (Catalog # MAB360)
- ELISA Detection (Matched Antibody Pair)0.1-0.4 µg/mLHuman CCL20/MIP‑3 alphaBiotinylated Antibody (Catalog # BAF360)
- ELISA StandardRecombinant Human CCL20/MIP-3 alpha Protein (Catalog # 360-MP)
- NeutralizationMeasured by its ability to neutralize CCL20/MIP‑3 alpha -induced chemotaxis in the BaF3 mouse pro‑B cell line transfected with human CCR6. The Neutralization Dose (ND50) is typically 1-5 µg/mL in the presence of 10 ng/mL Recombinant Human CCL20/MIP‑3 alpha.
- ReconstitutionReconstitute at 0.5 mg/mL in sterile PBS.
- ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
- Stability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
- Baba, M. et al. (1997) J. Biol. Chem. 272:14893.
- Hromas, R. et al. (1997) Blood 89:3315.
- Greaves, D.R. et al. (1997) J. Exp. Med. 186:837.
- Entrez Gene IDs:6364 (Human); 20297 (Mouse); 29538 (Rat)
- Alternate Names:beta chemokine exodus-1; Beta-chemokine exodus-1; CC chemokine LARC; C-C motif chemokine 20; CCL20; chemokine (C-C motif) ligand 20; CKb4; exodus-1; LARC; LARCLiver and activation-regulated chemokine; MIP3 alpha; MIP-3 alpha; MIP-3a; MIP-3-alpha; MIP3AMacrophage inflammatory protein 3 alpha; SCYA20Small-inducible cytokine A20; small inducible cytokine subfamily A (Cys-Cys), member 20; ST38
Background:
CCL20, also known as LARC (Liver and Activation-regulated Chemokine) and as Exodus, is one of many novelbetachemokines identified through bioinformatics. CCL20 cDNA encodes a 96 amino acid (aa) residue precursor protein with a 26 aa residue signal peptide that is predicted to be cleaved to form the 70 aa residue mature secreted protein. CCL20 is distantly related to otherbetachemokines (20 - 28% aa sequence identity) and the gene for CCL20 has been mapped to chromosome 2 rather than 17.
CCL20 has been shown to be expressed predominantly in lymph nodes, appendix, PBL, fetal liver, fetal lung and several cell lines. The expression of CCL20 is strongly up-regulated by inflammatory signals and down-regulated by the anti-inflammatory cytokine IL-10. Synthetic or recombinant CCL20 has been shown to be chemotactic for lymphocytes and to inhibit proliferation of myeloid progenitors in colony formation assays. CCL20 has now been shown to be a unique functional ligand for CCR-6 (previously referred to as GPR-CY4, CKR-L3, or STRL22 orphan receptor), a chemokine receptor that is selectively and highly expressed in human dendritic cells derived from CD34+ cord blood precursors.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
2.加大辣根过氧化物酶标记的链霉亲和素;
我现在用商品化的试剂盒进行夹心法ELISA测定某抗体的浓度,盒子给定了4个标准品,标准品抗体浓度为70000~1000单位,测定步骤中要求对样品进行1:1000稀释后测定。
但是有的样本按照1:1000稀释后,最终OD值大于70000浓度的标准品的OD值,然后使用ELISACALC软件进行四参数拟合,超过了标准曲线的范围,就算不出来这个样品的浓度,但是如果在1000-70000之间的OD值就可以算出相应浓度。请教大神们,接下来我是否可以对样品进行1:2000,1:4000浓度稀释,算出结果后再×2、×4,算作此样品的浓度呢?还是直接给一个>70000的定性结果?或者可以有能算出来的其他软件?
Ps试剂盒中提及Dilutionlinearity(稀释线性?)为141%,这个是什么意思呢?
多谢!!
请大家帮帮忙,第一步加完抗原后必须封闭吗
目前,我用该蛋白的鼠源性单抗来包被ELISA板子,5%BSA37度封闭二小时后,洗涤四次后将板子分三个组加入抗原:其中一个组中加入的是我重组的蛋白,另一个组为用其它方法证实含该蛋白的人体内血清,最后一个组加入PBS。37度一小时后洗涤四次后每孔加入我制备的兔源性多抗。37度一小时洗涤六次后我再加入酶标记的抗兔的抗体37度40分钟后洗涤六次后TMB显色。
问题就在我显色后所有的孔都是阳性,其中以抗原为我的重组蛋白组与PBS组OD值最高,两组都可以达到1.8以上,而加入的抗原为人体血清组低,为0.6-1.0不等。
后面我优化条件,封闭液用过5%的脱脂奶粉,2%的BSA,包被的单抗浓度摸了梯度,加入的多抗也摸了梯度,酶标的抗体也摸了梯度。结果都没有改变,连趋势每次都是一样以重组蛋白组与PBS组OD最高。
今天我还试着把抗原换成其它蛋白也做出了强阳性?
请教各位高手,我的ELISA该如何往下面做了啊,是不是我的抗体本身有问题呢?
对了,我包被用的单抗是用GE公司的预装柱纯化的,很纯,在考染中是看不到一条杂带的。
ELISA双抗体夹心法(enzyme linked immunosorbent assay——sandwich technique)的原理是将特异性抗体结合到固相载体上形成固相抗体,然后和待检血清中的相应抗原结合形成免疫复合物,洗涤后再加酶标记抗体,与免疫复合物中抗原结合形成酶标抗体-抗原-固相抗体复合物,加底物显色,判断抗原含量。
生物帮有相关介绍。编码RNA http://doc.bio1000.com/show-3399.html
(2)封闭:将已包被的板用洗涤液洗涤2次,每孔加入120 μL封闭液,封闭一段时间,取出,甩干备用。
(3)竞争反应:在制备好的板中每孔加入50 μL系列浓度的标准品溶液和50 μL稀释好的酶标抗体溶液,孵育一段时间。
(4)洗板:用洗涤液洗涤5次。
(5)显色反应:每孔加入显色溶液100 μL,孵育一段时间。
(6)终止:每孔各加入终止液,在酶标仪上测定各孔的吸光值。


暂无品牌分类